Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company specializing in the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet medical needs. The company’s primary focus lies in targeting the soluble protein CCL24, a chemokine that plays a pivotal role in promoting fibrosis and inflammation. Chemomab has developed nebokitug, a first-in-class humanized monoclonal antibody designed to bind and block CCL24 activity, offering a novel therapeutic approach for severe and life-threatening conditions such as primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). These rare diseases lack established disease-modifying treatments, positioning Chemomab as a potential leader in addressing critical gaps in patient care.

Chemomab Therapeutics Ltd. currently does not generate revenue from commercialized products, as its lead candidate, nebokitug, remains in clinical development. The company’s future revenue streams will depend on the successful approval and commercialization of nebokitug, either through direct sales or strategic partnerships. Potential revenue sources include licensing agreements, milestone payments from collaborators, and eventual product sales in global markets. The company estimates the addressable market for PSC and SSc at over $2.5 billion combined, reflecting the significant commercial opportunity if nebokitug secures regulatory approval.

The company operates through the following segments:

• Drug Development: This segment focuses on the clinical and preclinical advancement of nebokitug, a monoclonal antibody targeting CCL24 for the treatment of fibrotic and inflammatory diseases. The segment encompasses Phase 1, Phase 2, and planned Phase 3 trials for PSC and SSc, as well as exploratory studies in other indications such as metabolic dysfunction-associated steatohepatitis (MASH). It also includes regulatory interactions, manufacturing partnerships, and intellectual property management to support the drug’s development pipeline.

• Research and Innovation: This segment drives the discovery and validation of novel therapeutic targets within fibrotic and inflammatory pathways. It leverages Chemomab’s expertise in chemokine biology and monoclonal antibody development to identify next-generation assets and expand the company’s pipeline. Activities include preclinical studies, biomarker research, and collaborations with academic institutions to explore the mechanistic role of CCL24 in disease progression.

Chemomab Therapeutics Ltd. occupies a distinctive position within the biotechnology industry, particularly in the niche of fibrotic and inflammatory diseases. The company’s competitive advantage stems from its pioneering focus on CCL24, a target with dual anti-fibrotic and anti-inflammatory properties, which differentiates nebokitug from competitors primarily addressing single pathways. While major pharmaceutical and biotechnology firms, such as Boehringer Ingelheim, Roche, and Gilead, are active in fibrotic disease research, Chemomab is the only company advancing a monoclonal antibody specifically targeting CCL24 in clinical development for PSC and SSc. The orphan drug and Fast Track designations granted to nebokitug by the FDA and EMA further enhance its regulatory and commercial prospects, providing potential expedited approval pathways and market exclusivity.

The company’s customer base consists primarily of patients suffering from rare fibrotic and inflammatory diseases, including those with PSC and SSc. These patients represent a high-unmet-need population, as current treatment options are limited to symptom management rather than disease modification. Chemomab also engages with healthcare providers, including gastroenterologists, hepatologists, and rheumatologists, who treat these conditions. Additionally, the company collaborates with academic research institutions, such as The Royal Free Hospital in London and the University of Florence, to advance scientific understanding and clinical development of nebokitug.